Company: CRL
Filing Date: 2025-04-02
Form Type: DEF 14A
Source: 0001104659-25-030908
Chunk: 40

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-04-02
Form: DEF 14A
Chunk 40
---
|:--|
| 2018 Incentive Plan                                        | ​ | ​ | ​                                                                                     | ​ |    708,779 | ​ | ​ | ​ | ​                                                                     | $ | 231.19 | ​ | ​ | ​ | ​                                                                                                                                     | ​ |    2,786,836 | ​ | ​ |
| Equity compensation plans not approved by security holders | ​ | ​ | ​                                                                                     | ​ |          — | ​ | ​ | ​ | ​                                                                     | ​ |      — | ​ | ​ | ​ | ​                                                                                                                                     | ​ |            — | ​ | ​ |
| Total                                                      | ​ | ​ | ​                                                                                     | ​ | 708,779(1) | ​ | ​ | ​ | ​                                                                     | ​ |      — | ​ | ​ | ​ | ​                                                                                                                                     | ​ | 2,786,836(2) | ​ | ​ |

(1) None of the options outstanding under any of our equity compensation plans include rights to any dividend equivalents ( i.e. , a right to receive from us a payment equal to dividend payments received by holders of our common stock or our other equity instruments). (2) The 2018 Incentive Plan utilizes a fungible pool concept where each share issued in connection with awards that do not have option-like features (full-value awards) is counted as 2.3 units and each share issued that is subject to options, stock appreciation rights, and other awards that expire no more than seven years from the date of grant is counted as 1.0 unit against the overall reserved and available shares. The following table provides additional information regarding the aggregate issuances under our existing equity compensation plans as of December 28, 2024:

| Category                                               
 ​                                                      | ​ 
 ​ | ​ 
 ​ | Number ofsecuritiesoutstanding 
 (a)                            |   |         |   | ​ 
 ​ | ​ 
 ​ | Weightedaverageexerciseprice 
 (b)                          |   |        |   | ​ 
 ​ | ​ 
 ​ | Weightedaverageterm 
 (c)                 |   |      |   | ​ 
 ​ |
|:-------------------------------------------------------|:--|:--|:-------------------------------|:--|--------:|:--|:--|:--|:-----------------------------|:--|-------:|:--|:--|:--|:--------------------|:--|-----:|:--|:--|
| Total number of